Bertrand Laura A, Thomas Lewis J, Li Peng, Buchta Claire M, Boi Shannon K, Orlandella Rachael M, Brown James A, Nepple Kenneth G, Norian Lyse A
Department of Urology, The University of Iowa Carver College of Medicine, Iowa City, IA.
Department of Biostatistics, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL.
Urol Oncol. 2017 Nov;35(11):661.e1-661.e6. doi: 10.1016/j.urolonc.2017.06.058. Epub 2017 Aug 7.
Obesity, typically defined as a body mass index (BMI)≥30kg/m, is an established risk factor for renal cell carcinoma (RCC) but is paradoxically linked to less advanced disease at diagnosis and improved outcomes. However, BMI has inherent flaws, and alternate obesity-defining metrics that emphasize abdominal fat are available. We investigated 3 obesity-defining metrics, to better examine the associations of abdominal fat vs. generalized obesity with renal tumor stage, grade, or R.E.N.A.L. nephrometry score.
In a prospective cohort of 99 subjects with renal masses undergoing resection and no evidence of metastatic disease, obesity was assessed using 3 metrics: body mass index (BMI), radiographic waist circumference (WC), and retrorenal fat (RRF) pad distance. R.E.N.A.L. nephrometry scores were calculated based on preoperative CT or MRI. Univariate and multivariate analyses were performed to identify associations between obesity metrics and nephrometry score, tumor grade, and tumor stage.
In the 99 subjects, surgery was partial nephrectomy in 51 and radical nephrectomy in 48. Pathology showed benign masses in 11 and RCC in 88 (of which 20 had stage T3 disease). WC was positively correlated with nephrometry score, even after controlling for age, sex, race, and diabetes status (P = 0.02), whereas BMI and RRF were not (P = 0.13, and P = 0.57, respectively). WC in stage T2/T3 subjects was higher than in subjects with benign masses (P = 0.03). In contrast, subjects with Fuhrman grade 1 and 2 tumors had higher BMI (P<0.01) and WC (P = 0.04) than subjects with grade 3 and 4 tumors.
Our data suggest that obesity measured by WC, but not BMI or RRF, is associated with increased renal mass complexity. Tumor Fuhrman grade exhibited a different trend, with both high WC and BMI associated with lower-grade tumors. Our findings indicate that WC and BMI are not interchangeable obesity metrics. Further evaluation of RCC-specific outcomes using WC vs. BMI is warranted to better understand the complex relationship between general vs. abdominal obesity and RCC characteristics.
肥胖通常定义为体重指数(BMI)≥30kg/m²,是肾细胞癌(RCC)的既定危险因素,但矛盾的是,它与诊断时疾病进展程度较低及预后改善相关。然而,BMI存在固有缺陷,且有强调腹部脂肪的替代肥胖定义指标。我们研究了3种肥胖定义指标,以更好地检验腹部脂肪与全身性肥胖分别与肾肿瘤分期、分级或R.E.N.A.L.肾计量评分之间的关联。
在一个前瞻性队列中,对99例接受肾肿块切除术且无转移疾病证据的患者,使用3种指标评估肥胖情况:体重指数(BMI)、影像学腰围(WC)和肾后脂肪(RRF)垫距离。根据术前CT或MRI计算R.E.N.A.L.肾计量评分。进行单因素和多因素分析,以确定肥胖指标与肾计量评分、肿瘤分级和肿瘤分期之间的关联。
在这99例患者中,51例行部分肾切除术,48例行根治性肾切除术。病理显示11例为良性肿块,88例为肾细胞癌(其中20例为T3期疾病)。即使在控制年龄、性别、种族和糖尿病状态后,WC仍与肾计量评分呈正相关(P = 0.02),而BMI和RRF则不然(分别为P = 0.13和P = 0.57)。T2/T3期患者的WC高于良性肿块患者(P = 0.03)。相比之下,Fuhrman 1级和2级肿瘤患者的BMI(P<0.01)和WC(P = 0.04)高于3级和4级肿瘤患者。
我们的数据表明,通过WC而非BMI或RRF测量的肥胖与肾肿块复杂性增加相关。肿瘤Fuhrman分级呈现不同趋势,高WC和BMI均与低级别肿瘤相关。我们的研究结果表明,WC和BMI不是可互换的肥胖指标。有必要进一步评估使用WC与BMI对肾细胞癌特定结局的影响,以更好地理解全身性肥胖与腹部肥胖和肾细胞癌特征之间的复杂关系。